Cargando…

Survival outcomes of CD34(+)CD38(−)LSCs and their expression of CD123 in adult AML patients

BACKGROUND AND AIM: Acute myeloid leukemia (AML) is one of the most common leukemias in adults. AML is generally regarded as a stem cell disease characterized by an accumulation of undifferentiated and functionally heterogeneous populations of cells, The aim of the present study was to identify leuk...

Descripción completa

Detalles Bibliográficos
Autores principales: Zahran, Asmaa M., Aly, Sanaa Shaker, Rayan, Amal, El-Badawy, Omnia, Fattah, Maged Abdel, Ali, Arwa Mohammed, ElBadre, Hala M., Hetta, Helal F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6183348/
https://www.ncbi.nlm.nih.gov/pubmed/30344921
http://dx.doi.org/10.18632/oncotarget.26118
_version_ 1783362702250344448
author Zahran, Asmaa M.
Aly, Sanaa Shaker
Rayan, Amal
El-Badawy, Omnia
Fattah, Maged Abdel
Ali, Arwa Mohammed
ElBadre, Hala M.
Hetta, Helal F.
author_facet Zahran, Asmaa M.
Aly, Sanaa Shaker
Rayan, Amal
El-Badawy, Omnia
Fattah, Maged Abdel
Ali, Arwa Mohammed
ElBadre, Hala M.
Hetta, Helal F.
author_sort Zahran, Asmaa M.
collection PubMed
description BACKGROUND AND AIM: Acute myeloid leukemia (AML) is one of the most common leukemias in adults. AML is generally regarded as a stem cell disease characterized by an accumulation of undifferentiated and functionally heterogeneous populations of cells, The aim of the present study was to identify leukemia stem cells in patients with AML and their correlations with treatment outcomes namely remission status, disease free survival, and overall survival. RESULTS: The mean percentages of CD34(+)CD38(-) and CD34(+)CD38(low/−)CD123(+) LSCs were 2.2± 0.4and 22.3± 2.6, respectively. The percentages of CD34(+)cells, CD34(+)CD38(-) and CD34(+)CD38(low/−)CD123(+) LSCs were significantly lower in AML patients with complete remission than those without complete response (P<0.001, P<0.004, P<0.001 respectively). The mean OS of all study patients was 20.03±1.2 months while the median OS was 21 months (95% CI=18.32-21.48). The mean DFS was 16.96±1.02 months and the median was 18 months (95% CI=8.9-11.4). DFS and OS were significantly higher among those who achieved CR than those without CR. In addition, there were significant negative effects of WBCs, CD34(+)cells, CD34(+)CD38(-) and CD34(+)CD38(-)CD123(+)LSCs on DFS and OS. PATIENTS AND METHODS: We investigated 30 patients with newly diagnosed AML; all patients underwent complete history taking, and thorough physical and clinical examination, complete blood count. Peripheral smears and bone marrow aspirates were also examined. Cytochemistry and immunophenotyping of leukemic cells were performed routinely in bone marrow using monoclonal antibodies. Flow cytometry was used to analyze leukemia stem cells and their expression of CD123. CONCLUSION: Our study elucidated that CD34+CD38-LSCs, with or without CD123+LSCs phenotype was present in a significant proportion of AML patients and it could be responsible for resistance to traditional treatments, and high percentage of MRD that was translated into significantly high number of non CR, poor DFS, and OS.
format Online
Article
Text
id pubmed-6183348
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-61833482018-10-19 Survival outcomes of CD34(+)CD38(−)LSCs and their expression of CD123 in adult AML patients Zahran, Asmaa M. Aly, Sanaa Shaker Rayan, Amal El-Badawy, Omnia Fattah, Maged Abdel Ali, Arwa Mohammed ElBadre, Hala M. Hetta, Helal F. Oncotarget Research Paper BACKGROUND AND AIM: Acute myeloid leukemia (AML) is one of the most common leukemias in adults. AML is generally regarded as a stem cell disease characterized by an accumulation of undifferentiated and functionally heterogeneous populations of cells, The aim of the present study was to identify leukemia stem cells in patients with AML and their correlations with treatment outcomes namely remission status, disease free survival, and overall survival. RESULTS: The mean percentages of CD34(+)CD38(-) and CD34(+)CD38(low/−)CD123(+) LSCs were 2.2± 0.4and 22.3± 2.6, respectively. The percentages of CD34(+)cells, CD34(+)CD38(-) and CD34(+)CD38(low/−)CD123(+) LSCs were significantly lower in AML patients with complete remission than those without complete response (P<0.001, P<0.004, P<0.001 respectively). The mean OS of all study patients was 20.03±1.2 months while the median OS was 21 months (95% CI=18.32-21.48). The mean DFS was 16.96±1.02 months and the median was 18 months (95% CI=8.9-11.4). DFS and OS were significantly higher among those who achieved CR than those without CR. In addition, there were significant negative effects of WBCs, CD34(+)cells, CD34(+)CD38(-) and CD34(+)CD38(-)CD123(+)LSCs on DFS and OS. PATIENTS AND METHODS: We investigated 30 patients with newly diagnosed AML; all patients underwent complete history taking, and thorough physical and clinical examination, complete blood count. Peripheral smears and bone marrow aspirates were also examined. Cytochemistry and immunophenotyping of leukemic cells were performed routinely in bone marrow using monoclonal antibodies. Flow cytometry was used to analyze leukemia stem cells and their expression of CD123. CONCLUSION: Our study elucidated that CD34+CD38-LSCs, with or without CD123+LSCs phenotype was present in a significant proportion of AML patients and it could be responsible for resistance to traditional treatments, and high percentage of MRD that was translated into significantly high number of non CR, poor DFS, and OS. Impact Journals LLC 2018-09-25 /pmc/articles/PMC6183348/ /pubmed/30344921 http://dx.doi.org/10.18632/oncotarget.26118 Text en Copyright: © 2018 Zahran et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Zahran, Asmaa M.
Aly, Sanaa Shaker
Rayan, Amal
El-Badawy, Omnia
Fattah, Maged Abdel
Ali, Arwa Mohammed
ElBadre, Hala M.
Hetta, Helal F.
Survival outcomes of CD34(+)CD38(−)LSCs and their expression of CD123 in adult AML patients
title Survival outcomes of CD34(+)CD38(−)LSCs and their expression of CD123 in adult AML patients
title_full Survival outcomes of CD34(+)CD38(−)LSCs and their expression of CD123 in adult AML patients
title_fullStr Survival outcomes of CD34(+)CD38(−)LSCs and their expression of CD123 in adult AML patients
title_full_unstemmed Survival outcomes of CD34(+)CD38(−)LSCs and their expression of CD123 in adult AML patients
title_short Survival outcomes of CD34(+)CD38(−)LSCs and their expression of CD123 in adult AML patients
title_sort survival outcomes of cd34(+)cd38(−)lscs and their expression of cd123 in adult aml patients
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6183348/
https://www.ncbi.nlm.nih.gov/pubmed/30344921
http://dx.doi.org/10.18632/oncotarget.26118
work_keys_str_mv AT zahranasmaam survivaloutcomesofcd34cd38lscsandtheirexpressionofcd123inadultamlpatients
AT alysanaashaker survivaloutcomesofcd34cd38lscsandtheirexpressionofcd123inadultamlpatients
AT rayanamal survivaloutcomesofcd34cd38lscsandtheirexpressionofcd123inadultamlpatients
AT elbadawyomnia survivaloutcomesofcd34cd38lscsandtheirexpressionofcd123inadultamlpatients
AT fattahmagedabdel survivaloutcomesofcd34cd38lscsandtheirexpressionofcd123inadultamlpatients
AT aliarwamohammed survivaloutcomesofcd34cd38lscsandtheirexpressionofcd123inadultamlpatients
AT elbadrehalam survivaloutcomesofcd34cd38lscsandtheirexpressionofcd123inadultamlpatients
AT hettahelalf survivaloutcomesofcd34cd38lscsandtheirexpressionofcd123inadultamlpatients